Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Study sponsor: Trevi Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2017-09-03Actual
Enrollment · participants36Actual
Source updated2025-05-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.